Sabine Charrier

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index2.9kcitations64works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(22), CAR-T cell therapy research(15), Breast Cancer Treatment Studies(11), RNA Interference and Gene Delivery(11), Cancer Treatment and Pharmacology(8)

Publications64 total

Vector copy number analysis using droplet digital PCR method in hematopoietic stem cells and T lymphocytes after lentiviral transduction: optimization and limitations
2024Open Access
Process Development and Manufacturing: EFFICIENT TRANSDUCTION OF T CELLS USING A SUSPENSION-BASED LENTIVIRAL VECTOR SYSTEM
Cytotherapy·2023
VCN Analysis Using Droplet Digital PCR Method in Hematopoietic Stem Cells and T Lymphocytes after Lentiviral Transduction: Optimization and Limitations
Re GEN Open·2022Open Access
Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID
Molecular Therapy — Methods & Clinical Development·2019· 23 citedOpen Access
Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling βAS3 Globin for Gene Therapy for Sickle Cell Disease
Molecular Therapy — Methods & Clinical Development·2018· 23 citedOpen Access
Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for <i>Ex Vivo</i> Gene Therapy of X-Linked Chronic Granulomatous Disease
Human Gene Therapy Clinical Development·2018· 36 cited
Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency
Molecular Therapy — Methods & Clinical Development·2018· 47 citedOpen Access
Pre-clinical development of a lentiviral vector expressing the anti-sickling beta AS3 globin for gene therapy for sickle-cell disease
Human Gene Therapy·2017
Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients
Blood·2017· 57 cited
Preclinical Development of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1)
2017
Preclinical Development of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1)
Blood·2016· 2 cited
690. Development of a Clinical Lentiviral Vector for Gene Therapy of SCID-X1
Molecular Therapy·2016Open Access
Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs
Current Gene Therapy·2015· 24 cited
Lymphopoiesis in transgenic mice over-expressing Artemis
Gene Therapy·2015· 7 cited
Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies
Nature Genetics·2015· 130 citedOpen Access
243. Pre-Clinical Development of Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
Molecular Therapy·2015Open Access
Outcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome
JAMA·2015· 374 citedOpen Access
Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor
Haematologica·2013· 10 citedOpen Access
Distinctive Serum miRNA Profile in Mouse Models of Striated Muscular Pathologies
PLoS ONE·2013· 100 citedOpen Access
Efficient mobilization and transduction of WASP-deficient haematopoietic cells in a murine model
UCL Discovery (University College London)·2012
page 1 of 4Next →

Frequent Co-authors

Anne Galy(22), P. Chollet(13), Adrian J. Thrasher(11), William Vainchenker(9), J Dauplat(9), H. Curé(8), Fabrice Kwiatkowski(8), Jean-Pierre Ferrière(7), Axel Schambach(6), Fulvio Mavilio(6), Michael Rothe(6), Isabelle Van Praagh(5), V. Feillel(5), M de Latour(5), Olivier Danos(5), Bernard Gjata(5), Valentina Poletti(5), Loı̈c Dupré(4), Samantha Scaramuzza(4), Alessandro Aiuti(4)